Hospital Profile
Name | Calais Regional Hospital |
---|
Type | Critical Access Hospital |
---|
Location | 24 Hospital Lane, Calais, Maine |
---|
Ownership | Voluntary non-profit - Private |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 201305 |
Patients' Experience Survey:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Calais Regional Hospital from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1922001049 |
Organization Name | CALAIS COMMUNITY HOSPITAL |
Address | 24 Hospital Ln, Calais, ME 04619 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 207-454-7521 |
News Archive
CRT agrees with AstraZeneca for AZD-3965 clinical trial
Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm have reached an agreement with AstraZeneca to take compound AZD-3965 a first-of-its-kind experimental drug to potentially treat a range of cancers into clinical trial.
Turing Pharmaceuticals completes $90 million Series A financing
Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer.
Scientists investigate how background noise affects brain activity
Have you ever found it difficult to focus on a task due to background noise? Scientists at the University of Alberta are studying just how these sounds impact our brain activity-and what that impact means for designing neurotechnology.
FDA approves Ampio's IND for Optina for treatment of diabetic macular edema
Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
New technique allows rapid, large-scale studies of gene function
Using a gene-editing system originally developed to delete specific genes, MIT researchers have now shown that they can reliably turn on any gene of their choosing in living cells.
Read more Medical News
› Verified 1 days ago
Structural Quality Measures:
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
CRT agrees with AstraZeneca for AZD-3965 clinical trial
Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm have reached an agreement with AstraZeneca to take compound AZD-3965 a first-of-its-kind experimental drug to potentially treat a range of cancers into clinical trial.
Turing Pharmaceuticals completes $90 million Series A financing
Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer.
Scientists investigate how background noise affects brain activity
Have you ever found it difficult to focus on a task due to background noise? Scientists at the University of Alberta are studying just how these sounds impact our brain activity-and what that impact means for designing neurotechnology.
FDA approves Ampio's IND for Optina for treatment of diabetic macular edema
Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
New technique allows rapid, large-scale studies of gene function
Using a gene-editing system originally developed to delete specific genes, MIT researchers have now shown that they can reliably turn on any gene of their choosing in living cells.
Read more News
› Verified 1 days ago